Hong Ren

机构：Xuzhou Medical College, Shanghai Jiao Tong University, Dalian Medical University, Shanghai Children's Medical Center, Lianyungang Oriental Hospital, Second Affiliated Hospital of Chongqing Medical University, The First People’s Hospital of Lianyungang, Heilongjiang Provincial Hospital, Kangda College of Nanjing Medical University, Nanjing Medical University, Chongqing Medical University · ORCID：0000-0002-4557-0918

发表论文 505 篇 · 总被引 10169 次 · h-index 46

代表论文

• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 33)
• Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial. (2026 · Journal of Clinical Oncology · 被引 4)
• The Pathogenesis and Prevention Strategies of Radiation-Induced Brain Injury (2025 · Cancer Management and Research · 被引 4)
• Subxiphoid Thoracoscopic Surgery Is Safe and Feasible for the Treatment of Anterior Mediastinal Teratomas: A Multicentre Retrospective Study (2025 · European Journal of Cardio-Thoracic Surgery · 被引 3)
• Ginsenoside Rk1 inhibits the malignant progression of lung cancer by inactivating the INSR/PI3K/AKT pathway (2025 · Tissue and Cell · 被引 3)
• Impact of a multiplex respiratory PCR panel on antibiotic stewardship in hospitalized pediatric pneumonia: a randomized clinical trial (2026 · European Journal of Pediatrics · 被引 1)